medigraphic.com
ISSN 2594-1518 (Digital)
ISSN 1405-0099 (Impreso)

2008, Número S1

<< Anterior Siguiente >>

Cir Gen 2008; 30 (S1)


Características clínicas de los tumores del estroma gastrointestinal

Medrano GR, Torres VS, González RD

Idioma: Español
Referencias bibliográficas: 31
Paginas: 17-22
Archivo PDF: 130.76 Kb.


RESUMEN

Los tumores del estroma gastrointestinal (GIST, por sus siglas en inglés) forman parte de una de las neoplasias malignas más estudiadas actualmente, ya que su localización (estómago, intestino delgado, recto, esófago, apéndice, vesícula biliar, páncreas, mesenterio, omento, retroperitoneo) y características clínicas delinean su comportamiento biológico y la posibilidad de tratarlos con las nuevas terapias moleculares blanco. Debido a que el tipo de morfología de estos tumores puede confundirse con otras neoplasias malignas, es necesario reunir los resultados de varios estudios, tales como ultrasonido endoluminal (USE), tomografía axial computarizada (TAC), tomografía por emisión de positrones (PET), para poder detectarlos, etapificarlos, dar un diagnóstico más preciso y poder detectar metástasis.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519.

  2. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Pathol 2000; 15: 1293-1301.

  3. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer 1995; 75: 154-170.

  4. Tran T, Davila JA, ElSerag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gatroenterol 2005; 100: 162-168.

  5. Tryggvason G, Gislason HG, Mafnusson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003; the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117: 289-293.

  6. Goetsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumors in underestimated: results of a nation-wide study. Eur J Cancer 2005; 41: 2868-2872.

  7. Alexander J, Eckardt, et al. Diagnosis of subepithelial tumor in the GI tract. Endoscopy, EUS and histology: bronze, silver, and gold standard? Gastrointestinal Endoscopy 2005; 62: 209-212.

  8. Polkowski M, Butruk E, Submucosal lesions. Gastrointest Endosc Clin N Am 2005; 15: 33-54.

  9. Hwang JH, Sauders MD, Rulyak SJ, Shaw S, Kimmey MB. A prospective study comparing endoscopy and EUS in the evaluation of GI subepithelial masses. Gastrointest Endosc 2005; 62: 202-208.

  10. Rösch T, Kapfer B, Will U, Baronius W, Strobel M Lorenz R, et al. Accuracy of endoscopic ultrasonography in upper gastrointestinal submucosal lesions: a prospective multicenter study. Scand J Gastroenterol 2002; 37: 856-62.

  11. Miettinen M, El-Riafi W, Sobin LH. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478-83.

  12. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.

  13. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.

  14. Dow N, Giblen G, Sobin LH, et al. Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol 2006; 23: 11-119.

  15. Demetri GD, Benjamin RS, Blanke C, et al. Optimal management of patients with gastrointestinal stromal tumors. Expansion and update of NCCN Clinical Practice Guidelines. JNCCN 2004; 2 (Suppl 1).

  16. Choi H, Charnsangavej Ch, de Castro FS, et al. CT Evaluation of the response of gastrointestinal stromal tumors after Imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR 2004; 183: 1619-1628.17. van den Abbele A, Badawi RD, Cliché J, et al. 18 FDG-PET predicts response to imatinib mesylate in patients with advanced gastrointestinal stromal tumors. In: Annual Meeting of American Society of Clinical Oncology. Alexandria, VA: American Society of Clinical Oncology, 2002, Abstract 1610.

  17. Holdsworth CH, Badawi RD, Manola JB, Kijewsky MF, Israel DA. CT and PET early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am J 2007; 189.

  18. Margolis DJA, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS. Molecular imaging techniques in body imaging. Radiology 2007; 245: 333-356.

  19. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25: 4104-4109.

  20. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Ann Oncol 2005; 16: 566-578.

  21. Choi H, Charnsangavej C, S. Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759.

  22. Andtbacka HI, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24.

  23. Linton KM, Taylor MB, Radford JA. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 2006; 79: e40-e44.

  24. Meyer MA, Aliberti S, Grignani G, Aglietta M, Juweid ME, Cheson BD. Positron-emission tomography in cancer therapy. N Engl J Med 2006; 354: 1958-1960.

  25. Choi HH, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: Role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. RadioGraphics 2006; 26: 481-495.

  26. Ryu M-H, Lee J-L, Chang HM, Kim TW, Kang HJ, Sohn HJ, Lee JS, Kang Y-K. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate Jpn. J Clin Oncol 2006; 36: 17-24.

  27. Erturk SM. CT Evaluation of gastrointestinal stromal tumors treated with imatinib mesylate. Am J Roentgenol 2005; 185: 1366-1366.

  28. Demetri GD, Robert B, et al. NCCN task force report: Management of patients with gastrointestinal stromal tumor-update of the NCCN Clinical Practice Guidelines. J NCCN 2007; 5 (Suppl 2): 51-29.

  29. Kim H-Ch, Jeong ML, Seung HCh, et al. Imaging of gastrointestinal stromal tumors. J Comput Assist Tomogr 2004; 28: 596-604.

  30. Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors radiologic features with pathologic correlation. RadioGraphics 2003; 23: 283-304.

  31. Kim H, Lee JM, Kim SH, et al. Primary gastrointestinal stromal tumors in the omentum and mesentery: CT findings and pathologic correlations. AJR Am J Roentgenol 2003; 180: 185-189.




2020     |     www.medigraphic.com